Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) - Stock analysts at William Blair issued their Q1 2026 earnings per share estimates for shares of Allogene Therapeutics in a research note issued to investors on Friday, March 14th. William Blair analyst S. Corwin expects that the company will post earnings per share of ($0.29) for the quarter. The consensus estimate for Allogene Therapeutics' current full-year earnings is ($1.28) per share. William Blair also issued estimates for Allogene Therapeutics' Q2 2026 earnings at ($0.29) EPS, Q3 2026 earnings at ($0.30) EPS and Q4 2026 earnings at ($0.30) EPS.
A number of other research analysts have also recently commented on ALLO. Citizens Jmp upgraded Allogene Therapeutics from a "market perform" rating to an "outperform" rating and set a $5.00 price objective on the stock in a research note on Friday. Canaccord Genuity Group restated a "buy" rating and issued a $14.00 price target on shares of Allogene Therapeutics in a report on Friday. Finally, Royal Bank of Canada reiterated an "outperform" rating and set a $10.00 price objective on shares of Allogene Therapeutics in a research note on Friday. One analyst has rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $9.40.
Check Out Our Latest Report on ALLO
Allogene Therapeutics Stock Performance
Allogene Therapeutics stock traded down $0.11 during trading on Monday, reaching $1.75. 1,710,970 shares of the company's stock were exchanged, compared to its average volume of 3,043,715. Allogene Therapeutics has a 52-week low of $1.32 and a 52-week high of $4.74. The firm has a market cap of $365.88 million, a price-to-earnings ratio of -1.12 and a beta of 1.02. The company's 50-day moving average is $1.93 and its two-hundred day moving average is $2.31.
Allogene Therapeutics (NASDAQ:ALLO - Get Free Report) last released its quarterly earnings data on Thursday, March 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.06.
Institutional Inflows and Outflows
Several hedge funds have recently made changes to their positions in ALLO. Curi RMB Capital LLC lifted its stake in Allogene Therapeutics by 47.5% during the third quarter. Curi RMB Capital LLC now owns 149,577 shares of the company's stock worth $419,000 after purchasing an additional 48,202 shares during the last quarter. Intech Investment Management LLC bought a new position in shares of Allogene Therapeutics in the 3rd quarter worth about $116,000. The Manufacturers Life Insurance Company boosted its holdings in shares of Allogene Therapeutics by 1.2% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 486,023 shares of the company's stock valued at $1,361,000 after buying an additional 5,642 shares during the period. BNP Paribas Financial Markets grew its position in shares of Allogene Therapeutics by 541.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 46,374 shares of the company's stock valued at $130,000 after buying an additional 39,145 shares during the last quarter. Finally, Erste Asset Management GmbH acquired a new stake in Allogene Therapeutics during the third quarter worth about $91,000. Institutional investors and hedge funds own 83.63% of the company's stock.
Insider Transactions at Allogene Therapeutics
In other news, insider Timothy L. Moore sold 14,746 shares of the stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $1.71, for a total transaction of $25,215.66. Following the transaction, the insider now owns 250,713 shares of the company's stock, valued at approximately $428,719.23. This trade represents a 5.55 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Zachary Roberts sold 27,199 shares of the business's stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $1.78, for a total value of $48,414.22. Following the completion of the sale, the executive vice president now directly owns 488,054 shares of the company's stock, valued at approximately $868,736.12. This represents a 5.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 52,710 shares of company stock valued at $92,125. 24.30% of the stock is currently owned by corporate insiders.
Allogene Therapeutics Company Profile
(
Get Free Report)
Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).
Recommended Stories
Before you consider Allogene Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Allogene Therapeutics wasn't on the list.
While Allogene Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
